Actively Recruiting
Research on the Heterogeneity of Taiwanese Breast Cancer Patients by Next Generation Sequencing (NGS) Tools
Led by vghtpe user · Updated on 2020-11-12
1875
Participants Needed
1
Research Sites
405 weeks
Total Duration
On this page
Sponsors
V
vghtpe user
Lead Sponsor
Y
YongLin Healthcare Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
The objectives of this study are: 1. To determine the difference in genetic profiling of subjects with breast cancer recurrence 2. To determine the comprehensive genetic profiling of subjects with late stage breast cancer 3. To determine the potential biomarkers for early detection and prognosis for breast cancer 4. To determine the genetic profiling of immune system in different subtypes of breast cancer By integrating and analyzing the data generated using the methods of NGS, these information can be used for: 1. Understanding the genetic profiling of different subtypes of breast cancer in Taiwan 2. Assessing the efficacy of different treatments in breast cancer subjects 3. Defining the molecular risk factors and predicting the potential risk of breast cancer recurrence 4. Assessing the immune repertoire and the potential effects of immunotherapy in breast cancer subjects 5. Developing new strategies in treating patients with triple negative or late stage of breast cancer
CONDITIONS
Official Title
Research on the Heterogeneity of Taiwanese Breast Cancer Patients by Next Generation Sequencing (NGS) Tools
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female subjects aged over 20 years old
- Confirmed diagnosis of primary invasive breast cancer and planning to receive treatments
- Subjects with breast cancer recurrence within 3 years after surgery who had surgery for primary breast cancer within 3 years prior to screening
- Subjects diagnosed with stage IV breast cancer beyond 3 years after surgery or receiving breast cancer treatments
- Availability of primary tumor FFPE tissues passing RNA quality check
- Eastern Cooperative Oncology Group (ECOG) Performance score less than or equal to 3
- Life expectancy of at least 3 months
- Written informed consent provided, including consent to provide paired FFPE tissues if recurrence within 3 years
You will not qualify if you...
- History of primary cancer other than breast cancer within 5 years prior to screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Taipei Veterans General Hospital
Taipei, Taiwan
Actively Recruiting
Research Team
H
Hsiang-Chung Tseng
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here